Do analysts recommend ASMB or RFL?

Assembly Biosciences currently has a consensus price target of $44.00, suggesting a potential upside of 62.96%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Assembly Biosciences is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Assembly Biosciences 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer AVIR or RFL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atea Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer RFL or ENTA?

Enanta Pharmaceuticals has a consensus target price of $20.29, suggesting a potential upside of 46.57%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enanta Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75

Do analysts prefer TENX or RFL?

Tenax Therapeutics currently has a consensus price target of $37.67, suggesting a potential upside of 2,239.54%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Tenax Therapeutics is more favorable than Rafael. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Rafael 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Rafael (RFL) Competitors

$1.97 -0.08 (-3.90%)

As of 10:01 AM Eastern

Compare

RFL vs. ASMB, AVIR, ENTA, FENC, and TENX

Should you buy Rafael stock or one of its competitors? MarketBeat compares Rafael with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Rafael include Assembly Biosciences (ASMB), Atea Pharmaceuticals (AVIR), Enanta Pharmaceuticals (ENTA), Adherex Technologies (FENC), and Tenax Therapeutics (TENX). These companies are all part of the "pharmaceuticals" industry.

How does Rafael compare to Assembly Biosciences?

Assembly Biosciences (NASDAQ:ASMB) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Assembly Biosciences has higher revenue and earnings than Rafael. Assembly Biosciences is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Assembly Biosciences	$71.10M	6.04	-$6.12M	-$0.11	N/A
Rafael	$920K	111.63	-$30.52M	-$0.68	N/A

Assembly Biosciences has a net margin of -8.98% compared to Rafael's net margin of -3,321.74%. Assembly Biosciences' return on equity of -4.21% beat Rafael's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Assembly Biosciences	-8.98%	-4.21%	-3.14%
Rafael	-3,321.74%	-41.27%	-35.32%

Assembly Biosciences currently has a consensus price target of $44.00, suggesting a potential upside of 62.96%. Given Assembly Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Assembly Biosciences is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Assembly Biosciences	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 3.5% of Assembly Biosciences shares are owned by insiders. Comparatively, 32.9% of Rafael shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Assembly Biosciences' average media sentiment score of 0.00 equaled Rafael'saverage media sentiment score.

Company	Overall Sentiment
Assembly Biosciences	Neutral
Rafael	Neutral

Assembly Biosciences has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market. Comparatively, Rafael has a beta of 0.33, meaning that its share price is 67% less volatile than the broader market.

Summary

Assembly Biosciences beats Rafael on 11 of the 14 factors compared between the two stocks.

How does Rafael compare to Atea Pharmaceuticals?

Atea Pharmaceuticals (NASDAQ:AVIR) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, earnings, valuation, profitability, risk, dividends and media sentiment.

Rafael has higher revenue and earnings than Atea Pharmaceuticals. Rafael is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.11	N/A
Rafael	$920K	111.63	-$30.52M	-$0.68	N/A

Atea Pharmaceuticals has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Atea Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atea Pharmaceuticals	N/A	-57.01%	-51.49%
Rafael	-3,321.74%	-41.27%	-35.32%

Atea Pharmaceuticals has a beta of 0.29, meaning that its stock price is 71% less volatile than the broader market. Comparatively, Rafael has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atea Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Atea Pharmaceuticals had 2 more articles in the media than Rafael. MarketBeat recorded 2 mentions for Atea Pharmaceuticals and 0 mentions for Rafael. Atea Pharmaceuticals' average media sentiment score of 0.78 beat Rafael's score of 0.00 indicating that Atea Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Atea Pharmaceuticals	Positive
Rafael	Neutral

86.7% of Atea Pharmaceuticals shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 21.6% of Atea Pharmaceuticals shares are held by insiders. Comparatively, 32.9% of Rafael shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Atea Pharmaceuticals and Rafael tied by winning 7 of the 14 factors compared between the two stocks.

How does Rafael compare to Enanta Pharmaceuticals?

Rafael (NYSE:RFL) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

Rafael has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market. Comparatively, Enanta Pharmaceuticals has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

In the previous week, Enanta Pharmaceuticals had 3 more articles in the media than Rafael. MarketBeat recorded 3 mentions for Enanta Pharmaceuticals and 0 mentions for Rafael. Enanta Pharmaceuticals' average media sentiment score of 0.34 beat Rafael's score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Rafael	Neutral
Enanta Pharmaceuticals	Neutral

Enanta Pharmaceuticals has a consensus target price of $20.29, suggesting a potential upside of 46.57%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Enanta Pharmaceuticals is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

11.3% of Rafael shares are held by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are held by institutional investors. 32.9% of Rafael shares are held by insiders. Comparatively, 11.5% of Enanta Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Enanta Pharmaceuticals has a net margin of -89.56% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Enanta Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rafael	-3,321.74%	-41.27%	-35.32%
Enanta Pharmaceuticals	-89.56%	-64.04%	-20.22%

Rafael has higher earnings, but lower revenue than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rafael	$920K	111.63	-$30.52M	-$0.68	N/A
Enanta Pharmaceuticals	$65.32M	6.16	-$81.89M	-$2.59	N/A

Summary

Enanta Pharmaceuticals beats Rafael on 10 of the 16 factors compared between the two stocks.

How does Rafael compare to Adherex Technologies?

Adherex Technologies (NASDAQ:FENC) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

Adherex Technologies has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Rafael has a beta of 0.33, indicating that its stock price is 67% less volatile than the broader market.

Adherex Technologies has higher revenue and earnings than Rafael. Adherex Technologies is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adherex Technologies	$44.64M	8.87	-$9.74M	-$0.29	N/A
Rafael	$920K	111.63	-$30.52M	-$0.68	N/A

55.5% of Adherex Technologies shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 10.7% of Adherex Technologies shares are held by company insiders. Comparatively, 32.9% of Rafael shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Adherex Technologies has a net margin of -17.12% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Adherex Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adherex Technologies	-17.12%	-43.87%	-11.35%
Rafael	-3,321.74%	-41.27%	-35.32%

Adherex Technologies currently has a consensus price target of $15.40, indicating a potential upside of 36.40%. Given Adherex Technologies' stronger consensus rating and higher possible upside, equities research analysts plainly believe Adherex Technologies is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Adherex Technologies had 6 more articles in the media than Rafael. MarketBeat recorded 6 mentions for Adherex Technologies and 0 mentions for Rafael. Adherex Technologies' average media sentiment score of 0.22 beat Rafael's score of 0.00 indicating that Adherex Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Adherex Technologies	Neutral
Rafael	Neutral

Summary

Adherex Technologies beats Rafael on 13 of the 17 factors compared between the two stocks.

How does Rafael compare to Tenax Therapeutics?

Tenax Therapeutics (NASDAQ:TENX) and Rafael (NYSE:RFL) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Tenax Therapeutics has a net margin of 0.00% compared to Rafael's net margin of -3,321.74%. Rafael's return on equity of -41.27% beat Tenax Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenax Therapeutics	N/A	-61.54%	-57.42%
Rafael	-3,321.74%	-41.27%	-35.32%

Tenax Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Rafael has a beta of 0.33, meaning that its stock price is 67% less volatile than the broader market.

In the previous week, Tenax Therapeutics had 6 more articles in the media than Rafael. MarketBeat recorded 6 mentions for Tenax Therapeutics and 0 mentions for Rafael. Tenax Therapeutics' average media sentiment score of 0.58 beat Rafael's score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tenax Therapeutics	Positive
Rafael	Neutral

1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 11.3% of Rafael shares are held by institutional investors. 10.8% of Tenax Therapeutics shares are held by insiders. Comparatively, 32.9% of Rafael shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Rafael has higher revenue and earnings than Tenax Therapeutics. Rafael is trading at a lower price-to-earnings ratio than Tenax Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenax Therapeutics	N/A	N/A	-$52.60M	-$1.48	N/A
Rafael	$920K	111.63	-$30.52M	-$0.68	N/A

Tenax Therapeutics currently has a consensus price target of $37.67, suggesting a potential upside of 2,239.54%. Given Tenax Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Tenax Therapeutics is more favorable than Rafael.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenax Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Rafael	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Tenax Therapeutics beats Rafael on 9 of the 16 factors compared between the two stocks.

Get Rafael News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RFL vs. The Competition

Export

Metric	Rafael	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$106.81M	$11.85B	$7.00B	$24.11B
Dividend Yield	N/A	2.69%	2.58%	3.69%
P/E Ratio	-3.02	790.96	270.57	29.19
Price / Sales	111.63	972.15	659.56	13.03
Price / Cash	N/A	15.12	28.89	19.37
Price / Book	1.03	10.36	11.20	4.91
Net Income	-$30.52M	$2.78B	$3.45B	$1.06B
7 Day Performance	-1.45%	2.80%	3.39%	1.65%
1 Month Performance	-11.47%	-0.60%	-0.72%	2.63%
1 Year Performance	20.50%	192.58%	77.42%	20.40%

Rafael Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RFL Rafael	0.2581 of 5 stars	$1.97 -3.9%	N/A	+26.7%	$102.44M	$920K	N/A	20
ASMB Assembly Biosciences	1.6328 of 5 stars	$26.59 +0.5%	$44.00 +65.5%	+11.3%	$422.60M	$71.10M	N/A	100	Gap Up
AVIR Atea Pharmaceuticals	0.9539 of 5 stars	$5.10 +2.2%	N/A	+55.3%	$405.35M	N/A	N/A	70	Upcoming Earnings
ENTA Enanta Pharmaceuticals	2.3181 of 5 stars	$13.68 +2.5%	$20.29 +48.3%	+99.6%	$397.52M	$65.32M	N/A	160	News Coverage
FENC Adherex Technologies	3.879 of 5 stars	$11.35 +4.7%	$15.40 +35.7%	+38.9%	$395.00M	$44.64M	N/A	10	Upcoming Earnings Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:RFL) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rafael (RFL) Competitors

RFL vs. ASMB, AVIR, ENTA, FENC, and TENX

How does Rafael compare to Assembly Biosciences?

Summary

How does Rafael compare to Atea Pharmaceuticals?

Summary

How does Rafael compare to Enanta Pharmaceuticals?

Summary

How does Rafael compare to Adherex Technologies?

Summary

How does Rafael compare to Tenax Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFL vs. The Competition

Rafael Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rafael (RFL) Competitors

RFL vs. ASMB, AVIR, ENTA, FENC, and TENX

How does Rafael compare to Assembly Biosciences?

Which has preferable valuation and earnings, ASMB or RFL?

Is ASMB or RFL more profitable?

Do analysts recommend ASMB or RFL?

Do institutionals & insiders hold more shares of ASMB or RFL?

Does the media favor ASMB or RFL?

Which has more risk and volatility, ASMB or RFL?

Summary

How does Rafael compare to Atea Pharmaceuticals?

Which has higher earnings & valuation, AVIR or RFL?

Is AVIR or RFL more profitable?

Which has more volatility & risk, AVIR or RFL?

Do analysts prefer AVIR or RFL?

Does the media favor AVIR or RFL?

Do institutionals & insiders believe in AVIR or RFL?

Summary

How does Rafael compare to Enanta Pharmaceuticals?

Which has more risk and volatility, RFL or ENTA?

Does the media refer more to RFL or ENTA?

Do analysts prefer RFL or ENTA?

Do insiders & institutionals hold more shares of RFL or ENTA?

Is RFL or ENTA more profitable?

Which has higher earnings and valuation, RFL or ENTA?

Summary

How does Rafael compare to Adherex Technologies?

Which has more risk and volatility, FENC or RFL?

Which has better valuation & earnings, FENC or RFL?

Do institutionals and insiders hold more shares of FENC or RFL?

Is FENC or RFL more profitable?

Do analysts rate FENC or RFL?

Does the media prefer FENC or RFL?

Summary

How does Rafael compare to Tenax Therapeutics?

Is TENX or RFL more profitable?

Which has more risk and volatility, TENX or RFL?

Does the media prefer TENX or RFL?

Do institutionals & insiders hold more shares of TENX or RFL?

Which has better valuation and earnings, TENX or RFL?

Do analysts prefer TENX or RFL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RFL vs. The Competition

Rafael Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools